HAYWARD, Calif., Nov. 14, 2011 /PRNewswire/ -- GenturaDx today announced that it will present data from alpha studies performed in Q2 2011 at the Association for Molecular Pathology 2011 Annual Meeting on Friday, November 18 from 2:15 p.m. to 3:30 p.m. Poster number ID 23 titled "Comparison Of Assay Performance Between Cell Culture And A Rapid Automated Molecular Test For HSV Typing Of Clinical Samples"will address the capability of the GenturaDx IDbox System to detect HSV 1/2 as compared with non-molecular methods. Lead author Nathalie Visomblin, Chief Scientific Officer/Co-Founder Dr. Jesus Ching, and Senior Vice President of Research and Development Dr. Geoff McKinley will be on hand to answer questions.
The GenturaDx IDbox System will be on display at booth 721. GenturaDx's fully automated molecular diagnostics platform, the IDbox System and its initial HSV 1/2 assay, are currently in beta testing with clinical trials beginning in 2012. The IDbox System is a compact, fully integrated system that can handle multiple sample types and assay chemistry options. With a broad menu of infectious disease tests and a true press play and walk away technology, the IDbox System will be the first to enable labs to meet both increasing clinical demand for molecular testing while maximizing laboratory efficiency.
About GenturaDx
GenturaDx is a molecular diagnostic company focused on making high-performance molecular diagnostics both affordable and practical for any laboratory to perform. The company is developing a fully integrated, automated instrument that conducts testing using a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform incorporates sample preparation with proprietary, real-time PCR amplification and detection, reducing the risk of contamination and saving time. The platform's unique engineering design and intuitive interface relies on semi-batch processing capability while improving clinical value by offering multiple molecular targets in a single test. For more information, go to www.GenturaDx.com.
SOURCE GenturaDx
